Suppr超能文献

巴基斯坦胰腺导管腺癌人群的蛋白质组学生物标志物分析:一项回顾性队列研究。

Proteomic biomarkers profiling in Pakistani pancreatic ductal adenocarcinoma population: a retrospective cohort study.

作者信息

Ali Saleema Mehboob, Adnan Yumna, Ahmad Zubair, Chawla Tabish, Ali Sm Adnan

机构信息

Department of Surgery, Aga Khan University Hospital, Stadium Road P.O. Box 3500, Karachi, 74800, Pakistan.

Department of Pathology & Laboratory Medicine, Aga Khan University Hospital, Stadium Road P.O. Box 3500, Karachi, 74800, Pakistan.

出版信息

Biomark Med. 2024;18(21-22):969-982. doi: 10.1080/17520363.2024.2416888. Epub 2024 Nov 7.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers. Research in various cancers suggests that investigating target biomarkers may provide directions to precision medicine. However, expression of biomarkers varies across different populations. The biomarker profile of Pakistani patients with PDAC remains unexplored. We conducted a study on 109 patients to analyze a panel of four proteins (KRAS, p53, BRCA1 and APC) using formalin-fixed paraffin-embedded tumor samples. After confirmation of diagnosis and appropriate tumor content, tissues were processed with antibody specific immunohistochemistry experiments. Subsequently, independent microscopic observation was conducted by two pathologists using scoring criteria specific for each antibody. Statistical analysis showed that negative expression of p53 was significantly associated with positive expression of BRCA1 ( = 0.000) and APC ( = 0.007). The expression of BRCA1 was also found significantly associated with APC ( = 0.028). None of the protein showed association with overall survival or patient demographics. Moreover, KRAS expression was shown to be significantly associated with perineural invasion ( = 0.005). This is the first study that investigates protein biomarker expression in a large cohort of Pakistani PDAC patients. The findings from the study may provide directions about the population specific biomarkers and targeted therapies for these patients.

摘要

胰腺导管腺癌(PDAC)是侵袭性最强的癌症之一。对各种癌症的研究表明,研究靶向生物标志物可能为精准医学提供方向。然而,生物标志物的表达在不同人群中存在差异。巴基斯坦PDAC患者的生物标志物谱仍未得到探索。我们对109名患者进行了一项研究,使用福尔马林固定石蜡包埋的肿瘤样本分析一组四种蛋白质(KRAS、p53、BRCA1和APC)。在确诊并确定合适的肿瘤含量后,用抗体特异性免疫组织化学实验处理组织。随后,由两名病理学家使用每种抗体特有的评分标准进行独立的显微镜观察。统计分析表明,p53的阴性表达与BRCA1(P = 0.000)和APC(P = 0.007)的阳性表达显著相关。还发现BRCA1的表达与APC显著相关(P = 0.028)。没有一种蛋白质与总生存期或患者人口统计学特征相关。此外,KRAS表达与神经周围侵犯显著相关(P = 0.005)。这是第一项在大量巴基斯坦PDAC患者队列中研究蛋白质生物标志物表达的研究。该研究结果可能为这些患者提供关于人群特异性生物标志物和靶向治疗的方向。

相似文献

1
Proteomic biomarkers profiling in Pakistani pancreatic ductal adenocarcinoma population: a retrospective cohort study.
Biomark Med. 2024;18(21-22):969-982. doi: 10.1080/17520363.2024.2416888. Epub 2024 Nov 7.
3
Elevated KRAS protein level is associated with better survival in pancreatic cancer.
BMC Cancer. 2025 Jul 1;25(1):1080. doi: 10.1186/s12885-025-14461-w.
8
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.
Clin Orthop Relat Res. 2025 Jan 1;483(1):39-48. doi: 10.1097/CORR.0000000000003161. Epub 2024 Jun 21.
9
UBE3C promotes pancreatic ductal adenocarcinoma progression by catalysing p53 ubiquitination.
Mol Biol Rep. 2025 Jun 24;52(1):633. doi: 10.1007/s11033-025-10751-5.

本文引用的文献

1
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer.
Curr Issues Mol Biol. 2024 Mar 23;46(4):2827-2844. doi: 10.3390/cimb46040177.
2
Prognostic Effects of RASSF1A, BRCA1, APC, and p16 Promoter Methylation in Ovarian Cancer: A Meta-Analysis.
Gynecol Obstet Invest. 2024;89(5):363-375. doi: 10.1159/000538673. Epub 2024 Apr 12.
3
Clinicopathologic characteristics and treatment outcomes of pancreatic cancer patients at a tertiary referral hospital in Kenya.
Ecancermedicalscience. 2024 Mar 19;18:1682. doi: 10.3332/ecancer.2024.1682. eCollection 2024.
4
Early elevations of RAS protein level and activity are critical for the development of PDAC in the context of inflammation.
Cancer Lett. 2024 Apr 1;586:216694. doi: 10.1016/j.canlet.2024.216694. Epub 2024 Feb 1.
5
Improving early diagnosis of pancreatic cancer in symptomatic patients.
Br J Gen Pract. 2023 Nov 30;73(737):534-535. doi: 10.3399/bjgp23X735585. Print 2023 Dec.
6
Next batter up! Targeting cancers with KRAS-G12D mutations.
Trends Cancer. 2023 Nov;9(11):955-967. doi: 10.1016/j.trecan.2023.07.010. Epub 2023 Aug 15.
7
Pancreatic cancer in young adults - an evolving entity?
Am J Cancer Res. 2023 Jul 15;13(7):2763-2772. eCollection 2023.
8
KRAS G12D and G12V Mediated by CANDDY Technology Independent of Ubiquitination.
Molecules. 2023 Jul 24;28(14):5600. doi: 10.3390/molecules28145600.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验